Mezzion PharmaLtd (A140410) Stock Overview
Develops, manufactures, and sells pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A140410 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mezzion Pharma Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩76,300.00 |
| 52 Week High | ₩86,600.00 |
| 52 Week Low | ₩25,450.00 |
| Beta | 0.68 |
| 1 Month Change | 6.86% |
| 3 Month Change | 32.24% |
| 1 Year Change | 134.05% |
| 3 Year Change | 463.10% |
| 5 Year Change | 28.96% |
| Change since IPO | 669.41% |
Recent News & Updates
Recent updates
Is Mezzion PharmaLtd (KOSDAQ:140410) Using Debt Sensibly?
Oct 18
Here's Why We're Watching Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation
Mar 13Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation
Nov 02Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit
Sep 27Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking
Mar 04We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon
Feb 05
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain
Dec 14Shareholder Returns
| A140410 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.5% | 2.3% | -1.2% |
| 1Y | 134.0% | 31.8% | 60.4% |
Return vs Industry: A140410 exceeded the KR Pharmaceuticals industry which returned 31.8% over the past year.
Return vs Market: A140410 exceeded the KR Market which returned 60.4% over the past year.
Price Volatility
| A140410 volatility | |
|---|---|
| A140410 Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A140410's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A140410's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Dean Park | www.mezzion.co.kr |
Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older.
Mezzion Pharma Co.,Ltd. Fundamentals Summary
| A140410 fundamental statistics | |
|---|---|
| Market cap | ₩2.32t |
| Earnings (TTM) | -₩21.89b |
| Revenue (TTM) | ₩7.75b |
Is A140410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140410 income statement (TTM) | |
|---|---|
| Revenue | ₩7.75b |
| Cost of Revenue | ₩6.24b |
| Gross Profit | ₩1.51b |
| Other Expenses | ₩23.39b |
| Earnings | -₩21.89b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -720.82 |
| Gross Margin | 19.43% |
| Net Profit Margin | -282.43% |
| Debt/Equity Ratio | 24.9% |
How did A140410 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 00:11 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mezzion Pharma Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |
| Sang-Hun Lee | iM Securities |
| Eun Jung Song | Nomura Securities Co. Ltd. |